Juvenile myelomonocytic leukemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 12: Line 12:


{{Hematological malignancy histology}}
{{Hematological malignancy histology}}
{{SIB}}
 


[[Category:Hematology]]
[[Category:Hematology]]

Latest revision as of 16:39, 9 August 2012

Juvenile myelomonocytic leukemia Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes of Juvenile myelomonocytic leukemia

Differentiating Juvenile myelomonocytic leukemia from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

CT

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Radiation Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Juvenile myelomonocytic leukemia pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Juvenile myelomonocytic leukemia pathophysiology

CDC on Juvenile myelomonocytic leukemia pathophysiology

Juvenile myelomonocytic leukemia pathophysiology in the news

Blogs on Juvenile myelomonocytic leukemia pathophysiology

to Hospitals Treating Juvenile myelomonocytic leukemia

Risk calculators and risk factors for Juvenile myelomonocytic leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Genetics

About 80% of JMML patients have some sort of genetic abnormality in their leukemia cells that can be identified with laboratory testing. This includes:

  • 15-20% of patients with neurofibromatosis 1 (NF1)
  • 25% of patients with mutations in one of the RAS family of oncogenes (only in their leukemia cells)
  • Another 35% of patients with a mutation in a gene called PTPN11 (again, only in their leukemia cells).

References

fi:Juveniili myelomonosyyttileukemia


Template:WikiDoc Sources